
    
      To begin to assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial
      deposition of temsirolimus or temsirolimus with dexamethasone in maintaining luminal patency
      and composite safety endpoints in patients with clinical evidence of moderate to severe
      claudication or critical limb ischemia with rest pain after revascularization of one or more
      angiographically significant lesion(s) in superficial femoral or popliteal arteries.
    
  